Following the release of Q2 earnings from major manufacturers in the neurology space;

Sheryl Tang, Medical Devices Analyst at GlobalData, a leading data and analytics company, offers her view:

“The decline in procedural volumes during the end of Q1 through to Q2 due to COVID-19 has severely impacted the neurology market, with both Abbott and LivaNova reporting a decrease in neuromodulation sales – one of the most heavily impacted portfolios – and Stryker experiencing decline across its neurotechnology and spine business unit.

“Given the non-essential nature of most neurology procedures, it one of the most heavily impacted markets. The current number of COVID-19 cases has been steadily increasing again globally in Q3, and GlobalData expects that, should countries revert back to a state of lockdown, the neurology market will struggle to recover in 2020.

“Major manufacturers have reported seeing some recovery at the end of June, with procedural volumes reaching 90% of pre-COVID levels on average in the US.”